Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2026
0mins
Should l Buy ZNTL?
Source: stocktwits
- Dose Selection: Zentalis has chosen the 400 mg dose for its ovarian cancer treatment due to its significantly higher response rate compared to the 300 mg dose, enhancing its competitive edge in clinical trials.
- Trial Progress: The company expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026, paving the way for potential regulatory approval and further business development.
- Stock Surge: Following a bullish analyst call, Zentalis's shares soared over 40% on Friday, reaching their highest level since June 2024, reflecting market confidence in the drug's success.
- Analyst Rating Upgrade: Guggenheim raised Zentalis's price target from $6 to $10, indicating increased confidence in the drug's chances of success in platinum-resistant ovarian cancer, suggesting a potential 56% upside from the current stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZNTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZNTL
Wall Street analysts forecast ZNTL stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.640
Low
4.00
Averages
6.60
High
10.00
Current: 4.640
Low
4.00
Averages
6.60
High
10.00
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zentalis Unveils New Data, Paving New Directions in Cancer Treatment
- Preclinical Data Highlights: Zentalis presented preclinical data at the AACR meeting showing that combinations of azenosertib with antibody-drug conjugates can induce complete tumor responses in models resistant to ADCs, indicating potential applications beyond ovarian cancer and opening new avenues for pipeline expansion.
- Significant Preclinical Efficacy: In a model resistant to the approved TOPO1i ADC, the combination of azenosertib and enfortumab vedotin achieved complete responses in 87.5% of mice, effectively preventing tumor progression even after treatment cessation, showcasing its potential in treating resistant tumors.
- Real-World Data Validation: The real-world data presented at AACR highlight that Cyclin E1-positive ovarian cancer patients face significantly worse clinical outcomes with standard therapies, underscoring the importance of azenosertib for this population and potentially supporting the upcoming DENALI and ASPENOVA studies.
- Strong Market Demand: Cyclin E1-positive patients had an average time to next treatment of 13.2 months post-first-line therapy, significantly lower than the 19.5 months for Cyclin E1-negative patients, emphasizing the urgent need for targeted therapies in this specific population and driving the clinical development of azenosertib.
See More
Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
- Dose Selection: Zentalis has chosen the 400 mg dose for its ovarian cancer treatment due to its significantly higher response rate compared to the 300 mg dose, enhancing its competitive edge in clinical trials.
- Trial Progress: The company expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026, paving the way for potential regulatory approval and further business development.
- Stock Surge: Following a bullish analyst call, Zentalis's shares soared over 40% on Friday, reaching their highest level since June 2024, reflecting market confidence in the drug's success.
- Analyst Rating Upgrade: Guggenheim raised Zentalis's price target from $6 to $10, indicating increased confidence in the drug's chances of success in platinum-resistant ovarian cancer, suggesting a potential 56% upside from the current stock price.
See More
Zentalis Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Zentalis Pharmaceuticals granted 36,000 non-qualified stock options to two new employees as an inducement for their employment, reflecting the company's commitment to attracting talent.
- Incentive Plan Context: The stock options were granted under Zentalis' 2022 Employment Inducement Incentive Award Plan, designed to attract individuals who were not previously employed by the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Exercise Price: The exercise price of the stock options is set at $2.57 per share, equal to the closing price of Zentalis' common stock on the grant date, ensuring that employee incentives are aligned with market performance.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring that employees remain with the company to realize their incentives, thereby enhancing retention motivation.
See More
Zentalis Pharmaceuticals Reports FY 2025 Financial Results
- Financial Performance: Zentalis Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.91, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $245.9 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Outlook: Given the reported losses, the market may adopt a cautious stance regarding Zentalis's future growth potential, necessitating close monitoring of subsequent strategic adjustments and financial improvement efforts.
- Competitive Industry Pressure: In the context of increasing competition within the pharmaceutical sector, Zentalis must accelerate its R&D and marketing efforts to enhance product acceptance and profitability.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer patients during the GOBLET Cohort 4 study, significantly surpassing the historical benchmark of 10%, indicating the therapy's substantial potential in a patient population with no FDA-approved options.
- Duration of Response: The study also revealed a median duration of response of approximately 17 months, far exceeding the standard treatment's 9.5 months, suggesting that pelareorep offers durable efficacy in heavily pretreated patients, addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for accelerated approval if the observed data can be replicated.
- Strategic Investment and Expansion: The company is enhancing its strategic positioning in gastrointestinal oncology by expanding its Scientific Advisory Board, further solidifying its market presence in anal cancer and other indications.
See More
Zentalis Unveils New Data, Paving New Directions in Cancer Treatment
- Preclinical Data Highlights: Zentalis presented preclinical data at the AACR meeting showing that combinations of azenosertib with antibody-drug conjugates can induce complete tumor responses in models resistant to ADCs, indicating potential applications beyond ovarian cancer and opening new avenues for pipeline expansion.
- Significant Preclinical Efficacy: In a model resistant to the approved TOPO1i ADC, the combination of azenosertib and enfortumab vedotin achieved complete responses in 87.5% of mice, effectively preventing tumor progression even after treatment cessation, showcasing its potential in treating resistant tumors.
- Real-World Data Validation: The real-world data presented at AACR highlight that Cyclin E1-positive ovarian cancer patients face significantly worse clinical outcomes with standard therapies, underscoring the importance of azenosertib for this population and potentially supporting the upcoming DENALI and ASPENOVA studies.
- Strong Market Demand: Cyclin E1-positive patients had an average time to next treatment of 13.2 months post-first-line therapy, significantly lower than the 19.5 months for Cyclin E1-negative patients, emphasizing the urgent need for targeted therapies in this specific population and driving the clinical development of azenosertib.
See More
Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
- Dose Selection: Zentalis has chosen the 400 mg dose for its ovarian cancer treatment due to its significantly higher response rate compared to the 300 mg dose, enhancing its competitive edge in clinical trials.
- Trial Progress: The company expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026, paving the way for potential regulatory approval and further business development.
- Stock Surge: Following a bullish analyst call, Zentalis's shares soared over 40% on Friday, reaching their highest level since June 2024, reflecting market confidence in the drug's success.
- Analyst Rating Upgrade: Guggenheim raised Zentalis's price target from $6 to $10, indicating increased confidence in the drug's chances of success in platinum-resistant ovarian cancer, suggesting a potential 56% upside from the current stock price.
See More
Zentalis Grants Stock Options to New Employees
- Stock Option Grant: On April 1, 2026, Zentalis Pharmaceuticals granted 36,000 non-qualified stock options to two new employees as an inducement for their employment, reflecting the company's commitment to attracting talent.
- Incentive Plan Context: The stock options were granted under Zentalis' 2022 Employment Inducement Incentive Award Plan, designed to attract individuals who were not previously employed by the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Exercise Price: The exercise price of the stock options is set at $2.57 per share, equal to the closing price of Zentalis' common stock on the grant date, ensuring that employee incentives are aligned with market performance.
- Vesting Arrangement: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, ensuring that employees remain with the company to realize their incentives, thereby enhancing retention motivation.
See More
Zentalis Pharmaceuticals Reports FY 2025 Financial Results
- Financial Performance: Zentalis Pharmaceuticals reported a FY 2025 GAAP EPS of -$1.91, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, the company had $245.9 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Outlook: Given the reported losses, the market may adopt a cautious stance regarding Zentalis's future growth potential, necessitating close monitoring of subsequent strategic adjustments and financial improvement efforts.
- Competitive Industry Pressure: In the context of increasing competition within the pharmaceutical sector, Zentalis must accelerate its R&D and marketing efforts to enhance product acceptance and profitability.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer during the GOBLET Cohort 4, significantly exceeding the historical benchmark of 10%, indicating its crucial clinical value in a setting with no FDA-approved treatment options.
- Duration of Response: Among 14 evaluable patients, the median duration of response for pelareorep reached approximately 17 months, far surpassing the standard treatment's 9.5 months, showcasing the drug's durable efficacy in heavily pretreated patients and addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for potential accelerated approval if the data is validated.
- Strategic Investment and Expert Support: The company expanded its Scientific Advisory Board by adding three globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, further strengthening its strategic positioning in the gastrointestinal oncology field.
See More
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
- Clinical Data Breakthrough: Oncolytics Biotech's pelareorep demonstrated a 29% objective response rate in anal cancer patients during the GOBLET Cohort 4 study, significantly surpassing the historical benchmark of 10%, indicating the therapy's substantial potential in a patient population with no FDA-approved options.
- Duration of Response: The study also revealed a median duration of response of approximately 17 months, far exceeding the standard treatment's 9.5 months, suggesting that pelareorep offers durable efficacy in heavily pretreated patients, addressing a critical unmet medical need.
- FDA Accelerated Approval Plans: Oncolytics plans to hold a Type C meeting with the FDA in Q1 2026 to discuss advancing pelareorep into a registration-directed clinical study, paving the way for accelerated approval if the observed data can be replicated.
- Strategic Investment and Expansion: The company is enhancing its strategic positioning in gastrointestinal oncology by expanding its Scientific Advisory Board, further solidifying its market presence in anal cancer and other indications.
See More
